Taiwan cancer drugs developer seeks Hong Kong bond issue ahead of IPO after delisting from Taipei

JHL Biotech, a Taiwan developer of cheaper alternatives to patent-protected biological drugs, has raised US$106 million from a convertible bond issue, ahead of its planned Hong Kong initial public offering (IPO) aiming to raise some US$250 million.
( read original story …)

Search your Hotel